Pharmaceutical Startup Sollievo Raising Capital via Equity Crowdfunding for New Drug Launch
Oct 27, 2022
Flagship drug Proviza® targets increasing safety for first responders and healthcare staff in crisis situations.
San Juan Capistrano, California Oct 27, 2022 (Issuewire.com) - Sollievo Pharmaceuticals seeks to improve the safety of healthcare providers with its first product, Proviza. Proviza is a fast-acting injectable sedative in development to address the rising incidence of injuries and abuse to healthcare staff when treating agitated and aggressive patients.
Nearly 50% of emergency physicians say they've been assaulted. 70% of emergency nurses reported being attacked on the job. The reasons for rising violence are numerous -- mental health issues, drug abuse, understaffed emergency departments -- but multiple experts emphasize the increase in emergency room patients. Such visits rose from 94.7 million in 1995 to 142.6 million in 2016, the American Hospital Association reports, and nearly half of U.S. hospital-associated medical care is delivered by emergency departments.
Sollievo CEO Robert Schultz, Ph.D., sees his company's development of Proviza as a feasible front-line solution. That's because Proviza is designed to be one of the fastest and most consistent sedatives of its kind. The benefits of such an approach are clear; patients suffering mental disturbances, including drug-induced violence, can quickly be rendered harmless before hurting anybody.
However, it's not just about the violent patient. Doctors express concern that disruption of the ED/ER harms other patients and increases wait times for others. Proviza aims to reduce the time the staff is involved in treating these patients - which benefits everyone seeking emergency treatment.
To invest or learn more about the offering visit https://bit.ly/3eO226N
The Sollievo corporate website - http://sollievopharm.com/
About Sollievo
Sollievo produces solutions to unmet medical needs by modifying existing drugs or formulations. Proviza®, their first product, will uniquely address the skyrocketing injury rates among doctors and nurses when treating acutely agitated and violent patients.
Sollievo founder & CEO Robert K Schultz, Ph.D., has over 40 years of experience in the pharmaceutical and medical device industries. Dr. Schultz previously served as President and Chief Operating Officer of REVA Medical, Inc., a San Diego-based medical device company.
Source :Sollievo Pharmaceuticals, Inc.
This article was originally published by IssueWire. Read the original article here.
More News
Crown sues insurer refusing to help it cover mammoth class action payout
Casino operator is suing a multinational insurer, which has declined to pay out a policy the gambling giant expects to help it fund a $72 million class action.
Australian fuel prices near six-month highs on US-Iran peace deal impasse
Average petrol prices climbed 10¢ a litre and diesel rose 14¢ last week to hit their highest levels since the second month of the Iran war.
Red Metal expands Qld footprint in hunt for copper elephants
Red Metal Ltd has swooped in on ground near its two projects in QLD, lodging 17 additional tenement applications for prospective iron oxide-copper-gold deposits.
Australia’s biggest gold miner rejects ‘opportunistic’ $38b takeover offer
South Africa’s Gold Fields offered to buy Northern Star Resources in a potential blockbuster deal, but was knocked back.
A 175-year-old golden rule in markets is starting to break
Gold has effectively always cost much more than silver, and nickel more than copper. But the age of electricity is starting to wreak havoc on accepted wisdom.
Critical Resources doubles down on South American gold grab
Critical Resources has continued its push into the South American nation of Suriname, grabbing a second gold project in the tiny, gold-rich country.
Dateline soars on Washington support for gold-rare earths restart
Dateline Resources has surged after securing heavyweight US Government backing in a legal push to restart work at its Colosseum gold-rare earths project in California.
Wall Street’s multitrillion-dollar question: Could bonds end the AI boom?
The sudden surge in US bond yields threatens a market trading at near record levels, and the boom in artificial intelligence-related stocks that has driven it.
Shares flat ahead of interest rate call as oil jumps
Australian shares had a shaky start to the week, with a slump in miners counterbalancing rallies in banks, utilities and health care stocks.
Is it OK to take an iced coffee into a job interview?
A viral post by a leading job recruiter has sparked an online firestorm. The heated debate that has followed isn’t really about iced coffee.
We should be wary of bots that claim to get us a better deal
Can AI-powered personal assistants break the “lazy tax”? Maybe, but there’s also a real risk they could misbehave.
Power struggle: The push for Australia’s coal plants to pay to pollute
A new fight has erupted over a push for coal-fired power plants to face tougher pollution laws to ensure they do not stay open beyond current closure dates.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.